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1. Introduction
Glioma is the most common primary tumors of the central nervous system, accounting ap‐
proximately for 30% of entire CNS tumors, and classified into four clinical grades as I to IV.
The most aggressive and lethal tumors is glioblastoma multiforme (GBM) with median sur‐
vival of only 14.6 months, mainly because of limited effects of conventional post-surgical
chemotherapeutic agents and irradiation [1]. In this chapter, we summarize chemotherapeu‐
tic agents for glioma focusing on their mechanism of anti-tumor action and the acquisition
of resistance to the agents.
2. Temozolomide
2.1. Mechanism of action
Temozolomide (TMZ) is an alkylating agent which is applied to the treatment of malignant
glioma including GBM. TMZ induces DNA methylation of guanine at O6 position (O6-MG;
6% of adducts formed), as well as 7-methylguanine (N7-MG; 70% of adducts formed), and 3-
methyladenine (N3-MA; 9% of adducts formed) [2]. O6-MG incorrectly pairs with thymine
and triggers the mismatch repair (MMR) system leading to double strand break of the ge‐
nome that result in the arrest of cell cycle and induction of apoptosis. N7-MG and N3-MA
are removed by the methylpurine glycosylase followed by AP endonuclease which are the
first two enzymes in the base excision repair (BER) pathway. Efficient BER system functions
and repairs DNA lesions in normal and tumor cells. 573 patients with newly diagnosed as
GBM were randomly assigned to be treated by radiotherapy alone or by radiotherapy plus
continuous daily medication of temozolomide [3]. At a median follow-up of 28 months, the
median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months
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with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-te‐
mozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-
rank test). The two-year survival rate was 26.5 percent with radiotherapy plus
temozolomide and 10.4 percent with radiotherapy alone.
2.2. MGMT – a key molecule for TMZ resistance
MGMT specifically removes the methyl/alkyl group from the O6-position of guanine and re‐
store the guanine to its normal form escaping from DNA strand breaks (Fig. 1). Thus, the ex‐
pression of MGMT in tumors has a protective effect against alkylating agents-dependent cell
death correlating between MGMT activity and TMZ resistance. MGMT expressing tumor cells
exhibit 4- to 10-folds increase of resistance to TMZ, BCNU, and their related compounds [4].
MGMT-mediated repair is unique compared with other DNA repair pathways because : (a) it
acts alone without relying on any other proteins or cofactors; (b) it transfers the alkyl group to
an internal cysteine residue in the protein, acting as both a transferase and an acceptor of the al‐
kyl-group; (c) it inactivates itself after receiving the alkyl-group from guanine, and thus, it is a
suicidal protein; (d) it repairs in a stoichiometric fashion. As one molecule of MGMT removes
one alkyl molecule, an excess of DNA adducts at the O6-position could completely deplete
MGMT. MGMT is ubiquitously expressed in normal human tissues [5] but is overexpressed in
all types of human tumors, including colon cancer, glioma, lung cancer, breast cancer, leuke‐
mia, lymphomas, and myeloma. These properties make MGMT as an important drug resist‐
ance factor and an ideal target for suppression of drug resistance [2].
2.3. Regulation of MGMT
2.3.1. Promoter methylation
It is well known that MGMT expression levels vary widely in tumor cells [6; 7]. Hyperme‐
thylation of CpG islands within the promoter region is associated with epigenetic inactiva‐
tion of the MGMT. In the EORTC trial with 206 GBM patients, MGMT promoter
methylation was observed in 45% cases [8]. In cases with methylated MGMT promoter
which means negative of MGMT expression, TMZ was effective as median survival was 21.7
months treated with TMZ and RT compared with 15.3 months with only RT (P = 0.007). A
study of German Glioma Network (GGN) also showed that MGMT promoter methylation
was associated with prolonged progression-free survival (PFS) and OS in patients receiving
TMZ [9]. Several other studies have also shown predictive and prognostic significance of
MGMT promoter methylation in GBM [10].
2.3.2. Transcriptional regulation
In the MGMT promoter region, there are several specific sequences for the binding of tran‐
scription factors including SP1, GRE, AP-1, and NF-κB, thus MGMT can be induced by glu‐
cocorticoids, cyclic AMP, protein kinase C activators, and NF-κB [11; 12; 13; 14]. p53 is also
reported to suppress MGMT expression by directly binding to the MGMT or by suppressing
the transcription factor of SP1 [15; 16]. In addition, MGMT expression can be induced by ra‐
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diation or other forms of DNA damages [17]. However, physiological roles and regulation
of MGMT induction is not elucidated.
Figure 1. MGMT and other DNA repair mechanisms deal with DNA damage produced by the methylating ther‐
apeutic drug, temozolomide (TMZ), in human cells. TMZ and related drugs cause potentially cytotoxic DNA lesions
such as O6-methylguanine (O6-MG, orange circle) and N7-methylguanine (N7-MG, brown circle). (i), MGMT (O6-MG
DNA methyltransferase) removes the O6-alkylguanine DNA adduct through covalent transfer of the alkyl group to the
conserved active-site cysteine and restores the guanine to normal. After receiving a methyl-group from O6-MG,
MGMT is inactivated, and subject to ubiquitin-mediated degradation. A similar suicidal enzyme reaction occurs when
MGMT transfers and accepts an alkyl-group from O6-benzylguanine (O6-BG), a therapeutic strategies. (ii), if an O6-MG
DNA adduct escapes MGMT repair, it would form a base pair with thymine (blue circle) during DNA replication. The
mismatched base pair of the persistent O6-MG with thymine is recognized by the mismatch repair pathway, resulting
in futile cycles of repair leading to cell death. (iii), N7-MG DNA adducts ( > 70% of total DNA adducts formed by TMZ)
are efficiently repaired by the base excision repair (BER) pathway, and normally they contribute little to the cytotoxici‐
ty of TMZ. Methoxyamine binds to AP sites produced by methylpurine glycosylase (MPG), the first step in BER process‐
ing. Methoxyamine-bound AP sites are refractory to AP endonuclease (APE, green circle) cleavage, resulting in the
blockage of the BER pathway. This leads to strand breaks, disrupted replication, and increased cytotoxicity of TMZ. Fig‐
ure 1 is adapted from L. Liu et al. Clin Cancer Res. 2006;12(2):328-331.
2.3.3. Post-transcriptional regulation
MGMT protein was reported to be degraded via the ubiquitin proteolytic pathway [18]. Ac‐
cording to the recent study, the correlation between MGMT promoter methylation and
MGMT protein expression was poor (p = 0.27) [19]. In silico analysis predicted potential
binding sites for several miRNAs within the 3'UTR of MGMT, suggesting a mechanism for
post-transcriptional regulation of MGMT.
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2.4. Candidate drugs for combination with TMZ
Strategies to potentiate the effecacy of TMZ by suppressing MGMT or BER pathway have
been examined. Pseudosubstrates of MGMT such as O6-benzylguanine were expected to
suppress drug resistance by depleting MGMT [20; 21; 22]. However, clinical trials did not
show significant restoration of TMZ sensitivity in patients with TMZ-resistant GBM [23].
IFN-β down-regulates the expression of MGMT and sensitizes resistant glioma to TMZ and
phase II study has been started [15; 24].
We discovered post-transcriptional regulation of MGMT by signal transducer and activator
of transcription-3 (STAT3) and demonstrated that STAT3 inhibitor or STAT3 knockdown
potentiated TMZ efficacy in TMZ-resistant GBM cell lines [25] (Fig 2). Furthermore, immu‐
nohistochemical analysis of 44 malignant glioma specimens demonstrated significant posi‐
tive correlation between expression levels of MGMT and phosphorylated STAT3 (pSTAT3)
(p<0.001, r=0.58) (Fig 2). Therefore, STAT3 inhibitor might be one of the candidate reagents
for combination therapy with TMZ for TMZ-resistant GBM patients.
2.5. Other molecules involving TMZ resistance
In spite of the correlation between promoter methylation of MGMT and temozolomide sen‐
sitivity, survival time of the patients who have methylated promoters of MGMT is still short
and this suggests the involvement of other mechanism in TMZ resistance. Especially, key
molecules of MMR, BER, and Fanconi anemia repair pathway such as MSH6 [26; 27], N-
methyl purine DNA glycosylase (MPG) [28], DNA polymerase β (Polβ) [28], alkylpurine-
DNA-N-glycosylase (APNG) [29] and FANCD1/BRCA2 [30] have been reported to affect to
TMZ resistance. The unfolded protein response regulator GRP78/BiP was shown to act as a
novel target for increased chemosensitivity in malignant gliomas [31]. Inhibition of Y-box
binding protein-1 (YB-1) slows the increased growth of GBM and sensitizes to temozolo‐
mide independent of MGMT [32]. High levels of HOXA9/HOXA10 gene expression were as‐
sociated with a shorter survival in pediatric high-grade glioma patient samples. [33].
Phosphatase and tensin homologue (PTEN) deficiency in GBM confers resistance to radia‐
tion and temozolomide that is reversed by the protease inhibitor nelfinavir [34].
Table 1. Candidate drugs for combiunation with TMZ. STAT3 indicates signal transducer and activator of
transcription-3; PARP, poly(ADP-ribose) polymerase; BER, base excision repair.
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Figure 2. Correlation between expression levels of MGMT and phosphorylated STAT3. (A) Immunoblot analysis
of MGMT in T98G treated with 200 mM of STAT3 inhibitor VI. Duration of the treatment is indicated at the top as 0 to
48hr. Medium change indicated removal of STAT3 inhibitor. The level of pSTAT3 was also evaluated (middle panel).
Actin is shown as a loading control (bottom panel). (B) Correlation between pSTAT3 and MGMT in 44 cases of malig‐
nant glioma specimens. x and y axes indicate score of positivity of pSTAT3 and MGMT, respectively. z axis indicates the
number of cases. n=44, correlation coefficient r=0.58, p<0.001. (A) Immunoblot analysis of MGMT in T98G treated
with 200 mM of STAT3 inhibitor VI. Duration of the treatment is indicated at the top as 0 to 48hr. Medium change
indicated removal of STAT3 inhibitor. The level of pSTAT3 was also evaluated (middle panel). Actin is shown as a load‐
ing control (bottom panel). (B) Correlation between pSTAT3 and MGMT in 44 cases of malignant glioma specimens. x
and y axes indicate score of positivity of pSTAT3 and MGMT, respectively. z axis indicates the number of cases. n=44,
correlation coefficient r=0.58, p<0.001.
3. Targeted molecular agents
3.1. Therapeutic targets in GBM
Identification of biological mechanisms contributing to GBM oncogenesis contributes to pro‐
vide appropriate targeted therapies to improve patient outcomes. In a large-scale multidi‐
mensional analysis performed by the Cancer Genome Atlas involving, the most frequent
gene amplifications were: epidermal growth factor receptor (EGFR) and platelet-derived
growth factor receptor α (PDGFRα), 2 transmembrane receptors with tyrosine kinase activi‐
ty; cyclin-dependent kinase 4 (CDK4), and murine double minute (MDM)2 and MDM4
which are suppressors for p53 [35]. The most frequent homozygous gene deletions were
Chemotherapeutic Agent for Glioma
http://dx.doi.org/10.5772/54353
419
CDKN2A, CDKN2B, and CDKN2C, which encode tumor suppressor proteins that suppress
CDK4 and CDK6, phosphatase and tensin homolog (PTEN), a tumor suppressor that inhib‐
its phosphatidylinositol-3 kinase (PI3K) signaling such as retinoblastoma (RB1), a cell-cycle
inhibitor as PARK2, a regulator of dopaminergic cell death, and neurofibromin 1 (NF1), a
negative regulator of the RAS signal transduction pathway. The most frequently mutated
genes were p53, PTEN, NF1, EGFR, human epidermal growth factor receptor 2 (HER2), RB1,
and PIK3R1 and PIK3CA-2 components/regulators of the PI3K signaling pathway. This
study shows that several genes encoding proteins which are involved in signaling pathways
of receptor tyrosine kinases/PI3K, and p53 and the cyclin/RB1, are considerably altered in
GBM (Fig. 3). Another study has identified characteristic mutations in the active site of isoci‐
trate dehydrogenase 1 (IDH1) in 12% of patients with GBM. IDH1 mutations occurred in a
high proportion of young patients and in the majority of secondary GBM cases and were as‐
sociated with increased OS (3.8 years), compared with wild-type IDH1 (1.1 years) [36]. This
may be due to increased tumor sensitivity to chemotherapy, although a large controlled ser‐
ies in the German Glioma Network did not find any association between prolonged survival
of patients with tumors with IDH1 mutations and administration of a specific therapy [9].
Mutation of the IDH1 active site prevents conversion of isocitrate to α-ketoglutarate but al‐
lows the mutated enzyme to catalyze the nicotinamide dinucleotide phosphate-dependent
reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG) [37]. Accumulated 2HG ap‐
pears to act as an oncometabolite that contributes to glioma formation and malignant pro‐
gression. This observation is supported by data from patients with inherited 2-
hydroxyglutaric aciduria, in whom deficient 2HG dehydrogenase causes an accumulation of
brain 2HG. These patients have an increased risk of developing brain tumors, possibly be‐
cause of increased production of reactive oxygen species [38].
3.1.1. EGFR
EGFR is one of the most attractive therapeutic targets in GBM. Approximately 50% of GBM
overexpress EGFR and 25% express a constitutively active mutated form of EGFR known as
EGFRvIII, which has a large deletion in the extracellular domain and renders the receptor
ligand independent for signaling [39]. Overexpression of EGFR is more common in primary
tumors than in secondary GBM [40]. The deletion also renders a unique codon, which is not
found in the wild-type receptor, thereby creating a tumor-specific epitope that can be ex‐
ploited for therapeutic targeting. Increased EGFR signaling drives tumor cell proliferation,
invasiveness, motility, angiogenesis, and inhibition of apoptosis.
3.1.1.1. Gefitinib, Erlotinib, Lapatinib and Cetuximab
Small-molecules of EGFR inhibitor such as gefitinib and erlotinib are well tolerated in pa‐
tients with malignant gliomas, phase II trials have so far shown limited clinical benefit of er‐
lotinib in patients with either recurrent or newly diagnosed GBM, either in combination
regimens [41; 42; 43; 44] or as monotherapy [45]. Neither the EGFR/HER-2 inhibitor lapati‐
nib [46], nor the monoclonal antibody against EGFR, cetuximab [47], have proven to be ef‐
fective. Attempts to identify biomarkers to predict response to EGFR inhibitors have yielded
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conflicting results. There is no convincing evidence of a correlation between the drug effica‐
cy and the expression levels of EGFR in tumor tissue. In a phase I study, patients with glio‐
mas expressing high levels of EGFR and low levels of activated AKT had better responses to
erlotinib than did those with low EGFR expression and high levels of activated AKT [48].
Another study have shown significant correlation of therapeutic response of erlotinib and
the presence of EGFR deletion mutant variant III [49]. However, not all studies confirmed
these initial observations to predict the sensitivity to EGFR inhibitors [45].
3.1.2. PDGFR
PDGFR is a receptor tyrosine kinase with α and β isoforms. Overexpression of PDGFRα has
been demonstrated in astrocytoma and GBM, indicating a potential role in tumor develop‐
Figure 3. Genetic Alterations in Glioblastoma Occur Frequently in 3 Cellular Signaling Pathways. DNA altera‐
tions and copy number changes in the following signaling pathways are indicated in (a) receptor tyrosine kinase (RTK),
RAS, and phosphoinositol–3–kinase (PI3K); (b) p53 tumor suppressor; and (c)retinoblastoma (Rb) tumor suppressor.
Activating genetic alterations are shown in red. Genetic alterations that lead to a loss of function are indicated in blue.
In each pathway, the altered components, the type of alteration, and the percentage of tumors carrying each altera‐
tion are shown. Blue boxes contain the total percentages of glioblastomas with alterations in at least 1 known compo‐
nent gene of the designated pathway. Figure 3 is adapted from The Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature
2008;455(7216):1061–1068.
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ment [50]. Several PDGFR-targeting agents have been developed that may have therapeutic
potential against tumors with elevated PDGFR expression.
3.1.2.1. Sorafenib, Imatinib and Tandutinib
Sorafenib is an orally available antiangiogenic agent that inhibits tumor cell growth and pro‐
liferation by blocking the action of intracellular and receptor kinases, including PDGFR,
RAF kinase, VEGFR2, and c-KIT [51]. In human GBM cell lines, sorafenib inhibited prolifera‐
tion synergistically in combination with bortezomib, a proteosome inhibitor [52], and rot‐
tlerin, an experimental inhibitor of protein kinase C [53]. A phase II trial found that first-line
TMZ and radiotherapy followed by TMZ plus sorafenib was tolerated by patients with
GBM, although preliminary efficacy data for this regimen (median PFS duration, 6 months;
12-month PFS rate, 16%) were similar to data for standard therapy.
Imatinib mesylate, a small-molecule inhibitor for PDGFR, ABL, and c-KIT, was reported to
have significant antitumor activity both in vitro and in vivo as orthotopic glioma models (Kil‐
ic et al 2000). Especially, preclinical trials suggested that Imatinib have shows growth inhibi‐
tion in a subpopulation of CXCL12-expressing GBM cells [54] and radiosensitizes them [55].
However, in phase II trials involving recurrent GBM, imatinib alone or combined with hy‐
droxyurea had limited antitumor activity [56; 57; 58; 59; 60].
Tandutinib is an orally active inhibitor of PDGFR, FLT3, and c-KIT tyrosine kinase activity.
Although no preclinical data was available for tandutinib in GBM, 2 early-phase trials are
assessing tandutinib in recurrent/progressive GBM as monotherapy or combined with beva‐
cizumab. As correlation between increased gene expression levels of PDGFR and preclinical
data for therapeutic efficacy was reported, PDGFR may be a promising target for treating
GBM. However, the available clinical data suggest otherwise. Trial data of combination regi‐
mens involving PDGFR inhibitors are awaited [61].
3.1.3. VEGFR
There are multiple reasons for adapting anti-angiogenic drugs to the treatment of malignant
gliomas. Malignant glioma exhibits higher vascularization which is one of the pathological
hallmarks of GBM. One of the difficulties of developing effective treatments for gliomas has
been poor drug penetration through the blood-brain barrier. The dense network of angio‐
genic vessels in GBM typically display structural, functional, and biochemical abnormalities,
including large endothelial cell fenestrae, deficient basement membrane, decreased pericytes
and smooth muscle cells, haphazard interconnections with saccular blind-ended extensions,
complex tortuosity, and dysregulated transport pathways [62; 63; 64; 65; 66; 67]. Therefore,
by targeting the tumor vasculature, it is possible to bypass this dependence on drugs to pass
the blood-brain barrier to reach their targets. Further, there is also both experimental [68]
and clinical [69; 70] evidence that anti-angiogenic drugs can decrease vasogenic edema and
patients' requirement for corticosteroids which contributes to morbidity in this population.
The VEGF family of growth factors and their respective receptors are the best characterized
proangiogenic proteins in glioma. The VEGF family includes 6 secreted glycoproteins
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(VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth factor [PlGF]). VEGF-
A, the best characterized member, typically localizes adjacent to pseudopalisading necrosis
in GBM [71], and the levels of VEGF-A is increased in higher grade of glioma [72; 73], and is
associated with poor prognosis [74]. The VEGF receptor (VEGFR) family includes VEGFR-1
(Flt-1), VEGFR-2 (KDR), VEGFR-3, neuropilin-1 (NRP-1), and NRP-2, which exhibit different
binding affinities of the VEGF homologs. VEGFR-1 and VEGFR-2 regulate angiogenesis,
whereas VEGFR-3 regulates lymphangiogenesis. Vascular endothelial growth factor produc‐
tion and secretion by tumor cells is stimulated mainly by hypoxia, and malignant gliomas
are rapidly growing and innately hypoxic tumors. More specifically, VEGF-A binds to
VEGFR-2 expressed in blood vessels, which promotes endothelial cell migration and prolif‐
eration results in new blood vessel formation in a manner of paracrine signaling loop.
3.1.3.1. Bevacizumab
Bevacizumab, a recombinant humanized monoclonal antibody composed of human immu‐
noglobulin G1 (IgG1; 93%) and murine VEGF-binding complementarity-determining re‐
gions (7%), binds all isoforms of VEGF with high affinity and specificity [75]. Despite initial
reluctance to evaluate bevacizumab in patients with brain tumors owing to concerns of in‐
tracranial hemorrhage, a series of 29 patients with recurrent malignant glioma treated with
bevacizumab and irinotecan showed no significant hemorrhage with remarkable tumor re‐
gression as radiographic response rate of 66% compared with ordinal chemotherapeutic re‐
agents as rates of 9% [76; 77]. These results led rigorous prospective clinical trials of
bevacizumab in recurrent malignant gliomas. The combination of bevacizumab and irinote‐
can was studied in single-arm phase 2 trials for recurrent malignant glioma (n = 33) and
GBM (n = 35), showing response rates as 61% and 57%, and progression-free survival (PFS)
at 6 months as 55% and 46% [78; 79], respectively. These results were compared with previ‐
ous rates of PFS at 6 months as 9% to 15% for recurrent GBM and 17% to 31% for recurrent
malignant gliomas [80]. A large phase 2 trial randomized 167 patients of recurrent GBM to
analyze efficacy of combination of either bevacizumab or bevacizumab with irinotecan. This
noncomparative randomized study showed radiographic response rates as 28% and 38%,
and a PFS at 6 months of 43% and 50%, respectively [69]. In addition, patients treated with
bevacizumab often exhibit less vasogenic edema and decreased corticosteroid dependence
secondary to neutralization of VEGF, a known vascular permeability factor. Another phase 2
trial involved bevacizumab monotherapy in 48 heavily pretreated patients with recurrent
GBM [70]. The radiographic response rate was 35%, and the PFS6 rate was 29%. Ongoing
phase 3 studies are evaluating the combination of bevacizumab with temozolomide and ra‐
diotherapy. The results will be of great interest because of the uncertainty regarding the im‐
pact of bevacizumab on overall survival. Combinations of bevacizumab and other
chemotherapeutics or targeted molecular drugs are also currently in clinical trials.
3.1.3.2. Aflibercept
VEGF Trap (aflibercept) sequesters all isoforms of VEGF-A and PDGF as a soluble, recombi‐
nant, decoy receptor, composed of the second Ig domain of VEGFR-1 and the third Ig do‐
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main of VEGFR-2 bound to the hinge region of the Fc portion of human IgG1 [81]. Single
arm phase II study of aflibercept in recurrent malignant glioma was proceeded [82]. 42 pa‐
tients with GBM and 16 patients with malignant glioma who had received concurrent radia‐
tion and temozolomide therapies, and adjuvant temozolomide were enrolled at first relapse.
The 6-month progression-free survival rate was 7.7% for GBM cohort and 25% for patients
with malignant glioma. Overall radiographic response rate was 24% (18% for GBM and 44%
for malignant glioma). The median PFS was 24 weeks for patients with malignant glioma
(95% CI, 5 to 31 weeks) and 12 weeks for patients with GBM (95% CI, 8 to 16 weeks). A total
of 14 patients (25%) were removed from the study for toxicity, on average less than 2
months from treatment initiation. This study suggested Aflibercept monotherapy had mod‐
erate toxicity and minimal evidence of single-agent activity in unselected patients with re‐
current malignant glioma.
3.1.3.3. Cediranib
Several inhibitors for VEGFR tyrosine kinase have shown significant antiangiogenic and an‐
titumor activity in preclinical GBM models [83; 84; 85; 86; 87; 88], which may also enhance
cytotoxic therapy [89; 90; 91]. In addition, several these agents are undergoing evaluation in
phase I/II clinical trials, but only cediranib has advanced to phase III investigation. In an ini‐
tial phase II study of single-agent cediranib (45 mg/d), 27% of patients with recurrent malig‐
nant glioma exhibited a radiographic response and a 6-month PFS was 26%. In addition,
cediranib induced rapid normalization of tumor vasculature, including decreased diameter
of microvessels and diminished permeability, which reversed after cediranib interruption.
Adverse events including hypertension and fatigue were observed, and nearly half of the
patients required a dose reduction or interruption of therapy because of its toxicity [92].
3.1.3.4. Mechanisms of resistance to antiangiogenic therapy
Although antiangiogenic therapies prolong PFS of GBM patients, further progression of dis‐
ease is inevitable. Progression of tumors under antiangiogenic therapy cannot often be treat‐
ed successfully thereafter, and most patients die of the disease within a few months. In the
cediranib study, serum levels of the proangiogenic factors bFGF, stromal-derived factor 1
(SDF1), and soluble VEGFR2 increased at the time of failure [93]. The alternative proangio‐
genic pathways depends on these angiogenic factors may drive angiogenesis in the setting
of VEGFR inhibition. Furthermore, for many gliomas, particularly malignant gliomas, there
is often little evidence for vascular proliferation. As the individual infiltrating tumor cell
tends to grow along normal cerebral vasculature, and thus there is no need for tumor-associ‐
ated angiogenesis. Indeed, there is at least a theoretical concern that inhibition of angiogene‐
sis in malignant glioma may prevent the formation bulky tumor but has little effect on
sparsely infiltrative GBM cells results in little impact on OS of patients. Early clinical and
radiographic observations of patients treated with bevacizumab suggest that this may be the
case [94; 95]. Another concern is recent laboratory evidence that suggests that inhibition of
VEGF may actually increase invasiveness of tumor cells [96]. The infiltrative tumor cells are
often responsible for relapse leading to the death of patients.
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Combination of antiangiogenic and anti-invasion therapy may delay disease progression.
Studies of co-administration of cediranib (pan-VEGFR inhibitor) with cilengitide (integrin
inhibitor) and bevacizumab (neutralizing VEGF antibody) with dasatinib (PDGFRβ inhibi‐
tor) are ongoing. Another potential mechanism of resistance to antiangiogenic therapies in‐
volves increased PDGF signaling. PDGF stabilizes neovasculature by recruiting pericytes
and facilitating pericyte-endothelial cell interactions [97]. Preclinical data suggest that dual
VEGFR/PDGFR inhibition potentiates antiangiogenic efficacy and reduces resistance to ther‐
apy [98], and this approach is currently being evaluated in clinical trials.
3.1.4. c-MET
Aberrant signaling by hepatocyte growth factor (HGF) and its receptor MET has been ob‐
served in various tumors including GBM, and potential involvement in tumorigenesis and
metastasis has been reported [99]. Recently c-MET overexpression was detected in 18 (29%)
of 62 GBM with shorter median survival durations than those of little or no expression of c-
MET (median durations of survival, 11.7 vs 14.3 months) [100].
3.1.4.1. AMG102 and PF02341066
Inhibitors of HGF or c-MET have shown preclinical activity against GBM cell lines [99]. The
anti-HGF antibody AMG102 enhanced TMZ-induced inhibition of growth of GBM cell line
in vitro and in vivo as xenografts [101]. However, phase II trial suggests AMG 102 monother‐
apy did not significantly suppress tumor growth of recurrent GBM [102]. PF02341066, an or‐
ally available ATP-competitive inhibitor of c-MET inhibited growth and c-MET
phosphorylation of GBM in preclinical studies [103]. This molecule is currently under clini‐
cal investigation in patients with advanced cancers.
3.1.5. PI3K and related pathways
PI3K plays a role in intracellular signaling pathways regulating in cell  survival,  growth,
and  proliferation.  Activated  PI3K  is  recruited  to  the  cell  membrane  where  it  mediates
signaling after  activation of  receptor  tyrosine kinases.  Downstream targets  include AKT
for cell proliferation and survival; glycogen synthase kinase-3 (GSK-3) for regulation of c-
MYC;  and  mammalian  target  of  rapamycin  (mTOR)  for  regulation  of  protein  synthesis
and  negative  regulator  of  PI3K.  In  malignant  glioma,  PI3K/Akt/mTOR  signaling  is  fre‐
quently  activated  because  of  the  stimulation  of  receptor  tyrosine  kinases  as  EGFR,
PDGFR, and mesenchymal-epithelial transition factor (MET), mutation of oncogenic PI3K
subunits,  and/or  loss  of  PTEN tumor  suppressor  activity.  Therefore  inhibiting  the  PI3K
pathway may have therapeutic potential.
3.1.5.1. NVP-BEZ235 and Enzastaurin
NVP-BEZ235, an orally available kinase inhibitor for PDK1, mTOR, and PI3K, induced G1
arrest of a GBM cell line in vitro and enhanced TMZ efficacy in vivo [104]. NVP-BEZ235 treat‐
ment is currently in phase I trials involving patients with solid tumors.
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Enzastaurin,  a  PKC/PI3K/AKT inhibitor,  suppressed proliferation and induced apoptosis
via  a  caspase-dependent mechanism in GBM cells  in vitro [105].  In vivo  models showed
that enzastaurin combined with radiotherapy synergistically reduced tumor volume, radi‐
ation-induced satellite  tumor formation,  upregulation of  VEGF expression,  neovasculari‐
zation,  and GSK-3β  phosphorylation  [106].  In  phase  II  study  of  enzastaurin  in  patients
with recurrent heavily pretreated GBM showed that objective radiographic responses oc‐
curred in 25% of patients [107]. The subsequent phase III trial comparing lomustine and
enzastaurin at first or second recurrence was the first phase III trial to evaluate a target‐
ed therapy for recurrent GBM. Enzastaurin was well tolerated and had a better hemato‐
logic  toxicity  profile  but  did  not  have  superior  efficacy  compared  with  lomustine  in
patients with recurrent GBM [108].
3.1.6. SRC and SRC-Family kinases
SRC and SRC-Family Kinases (SFKs) are frequently activated in GBM [109] frequently due
to their overexpression [110]. SRC and SFKs are promiscuous regulators of multiple signal‐
ing pathways for cell proliferation, adhesion, migration, and invasion, which are important
processes in tumor invasion and metastasis.
3.1.6.1. Dasatinib
Dasatinib  is  a  potent  inhibitor  of  SRC and  SFKs  and  has  been  approved  for  the  treat‐
ment of certain types of leukemia on the basis of inactivation of BCR-ABL [111]. Dasati‐
nib also inhibits c-KIT and PDGFR [112]. In GBM cells, dasatinib inhibited migration and
induced  autophagy,  resulted  in  cell  death  which  was  enhanced  by  combination  with
TMZ [111; 113]. Dasatinib inhibited invasion, promoted tumor regression, induced apop‐
tosis  in  EGFRvIII-expressing  GBM,  and  enhanced  the  activity  of  anti-EGFR  antibodies
[111]. Trials of dasatinib are ongoing in GBM and several solid tumors. A phase I/II trial
involving patients with newly diagnosed GBM is assessing dasatinib combined with ra‐
diotherapy  and  concomitant  TMZ,  followed  by  adjuvant  dasatinib  plus  TMZ.  Trials  of
dasatinib for treatment of recurrent GBM include a phase II trial of dasatinib monothera‐
py,  a  phase  I  trial  of  dasatinib  in  combination  with  erlotinib,  and a  randomized phase
I/II  trial  of dasatinib in combination with CCNU that has started its phase I  component
with patients who have recurrent GBM.
3.1.7. Integrin
Integrin  plays  key  roles  regulating  cell  adhesion,  migration,  and  invasion.  In  addition
to  a  role  for  matrix-cell  contact,  integrin  also  activate  intracellular  signals  including
SRC-dependent  pathway.  In  various  tumors,  integrin  has  an  established  role  in  meta‐
stasis  and  angiogenesis  [114].  Therefore,  targeting  integrin  function  may  have  potential
for  treating GBM.
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Table 2. Targeted molecular agents currently in clinical development for high-grade glioma TKI indicates tyrosine
kinase inhibitor; SAHA, suberoylanilide hydroxamic acid; RGD, arginine-glycine-aspartate; STKI. serine-threnoine
kinase inhibitor; PKC, protein kinase C.




Cilengitide is a specific αV integrin inhibitor in clinical development. In a phase I/IIa tri‐
al,  cilengitide combined with the current standard of therapy in patients with newly di‐
agnosed GBM was well tolerated, with 6-month PFS as 69%. Methylation of promoter of
O6-methylguanine-DNA methyltransferase  (MGMT) predicts  a  higher  likelihood of  ach‐
ieving  6-month  PFS,  as  shown  by  increases  in  the  durations  of  PFS  and  OS  to  13.4
months  and 23.2  months,  respectively,  compared with  3.4  and 13.1  months  for  patients
without MGMT promoter methylation [115]. On the basis of these findings, a similar reg‐
imen is being compared with radiotherapy/TMZ alone in the phase III CENTRIC trial in
patients with newly diagnosed GBM with hypermethylated MGMT promoter. In a phase
IIa study of recurrent GBM, cilengitide monotherapy was well tolerated but was largely
inactive (6-month PFS rate, 15%); long-term disease stabilization was seen in a small sub‐
set of patients:  10% were progression free for 12 months,  and 5% were progression free
for 24 months [116].
3.1.8. Histone deacetylase inhibitor
Histone deacetylases (HDACs) are involved in multiple processes to lead malignant pheno‐
type of glioma including maintanance of stemness, angiogenesis, and resistance to DNA
damage.
3.1.8.1. Vorinostat
Vorinostat is an orally available inhibitor of class I and II HDAC approved for advance cuta‐
neous T cell lymphoma. In a phase II study of recurrent GBM, vorinostat monotherapy was
well tolerated and had modest clinical activity (6-month PFS rate, 15.2%; median OS dura‐
tion, 5.7 months) [117]. Vorinostat is currently being evaluated for use in newly diagnosed
and recurrent GBM as a combination therapy.
4. Conclusion
Although TMZ prolonged the survival of GBM patients, GBM are still immortal disease
with extremely poor prognosis because of acquisition of TMZ resistance. Therefore, other
therapeutic agents which suppress MGMT expression or attenuate TMZ resistance are high‐
ly desired. As the efficacy of single agent of targeted molecular therapy seems to be limited,
combination therapy should be evaluated since multi-pathway is involved in the chemore‐
sistance in GBM. An ‘tailor-made’ selection of chemotherapeutic agents for each GBM pa‐
tients based on molecular analysis is essential to obtain maximum efficacy of
chemotherapeutic agents.
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